# EDGAR Filing Document

**Accession Number:** 0001640546
**File Stem:** 0001193125-26-046463
**Filing Date:** 2026-2
**Character Count:** 11249
**Document Hash:** 7d6d051feb9faec481d4800aa110620b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-046463.hdr.sgml**: 20260211

**ACCESSION NUMBER**: 0001193125-26-046463

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260211

**DATE AS OF CHANGE**: 20260211

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Werewolf Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001785530
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823523180
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92515
- **FILM NUMBER:** 26620501

**BUSINESS ADDRESS:**
- **STREET 1:** 200 TALCOTT AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-952-0555

**MAIL ADDRESS:**
- **STREET 1:** 200 TALCOTT AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Longwood Fund III, L.P.
- **CENTRAL INDEX KEY:** 0001640546

**ORGANIZATION NAME:**
- **EIN:** 473818935
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** PRUDENTIAL TOWER
- **STREET 2:** SUITE 1555, 800 BOYLSTON ST.
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02199
- **BUSINESS PHONE:** 617-351-2590

**MAIL ADDRESS:**
- **STREET 1:** PRUDENTIAL TOWER
- **STREET 2:** SUITE 1555, 800 BOYLSTON ST.
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02199

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** Werewolf Therapeutics, Inc.

**Title of Class of Securities:** Common Stock

**CUSIP Number:** 95075A107

**Date of Event Which Requires Filing of this Statement:** 12/31/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Longwood Fund III GP, LLC | Names of Reporting Persons<br>Longwood Fund III GP, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1677082 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1677082 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1677082 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1677082 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>3.5% | Percent of Class Represented by Amount in Row (9)<br>3.5% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** (1)  All such shares are held of record by Longwood III (as defined in Item 2(a) below). Longwood III GP (as defined in Item 2(a) below) is the general partner of Longwood III and may be deemed to share voting and dispositive power with respect to these securities.
(2)  Based on 48,540,200 shares of the Issuer's Common Stock outstanding as of October 29, 2025, as reported by the Issuer's in its Form 10-Q for quarter ended September 30, 2025, filed with the United States Securities and Exchange Commission (the "SEC") on November 4, 2025 (the "Form 10-Q").

---

| 1. | Names of Reporting Persons<br>Longwood Fund III, L.P. | Names of Reporting Persons<br>Longwood Fund III, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1677082 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1677082 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1677082 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1677082 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>3.5% | Percent of Class Represented by Amount in Row (9)<br>3.5% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** (1) All such shares are held of record by Longwood III. Longwood III GP is the general partner of Longwood III and may be deemed to share voting and dispositive power with respect to these securities.
(2) Based on 48,540,200 shares of the Issuer's Common Stock outstanding as of October 29, 2025, as reported by the Issuer in the Form 10-Q.

---

**Item 1(a). Name of Issuer:**
Werewolf Therapeutics, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
200 Talcott Avenue, Floor 2, Watertown, MA 02472

**Item 2(a). Name of Person Filing:**
This Amendment No. 1 (this "Amendment") amends and supplements the Schedule 13G originally filed by Longwood Fund III, L.P. ("Longwood III") and Longwood Fund III GP, LLC ("Longwood III GP" and together with Longwood III, the "Reporting Persons") with the SEC on May 14, 2021 (the "Original 13G"). This Amendment is being filed by the Reporting Persons.

**Item 2(b). Address of Principal Business Office:**
The address of the principal business office of each Reporting Person is 800 Boylston Street, Suite 1715, Boston, MA 02199.

**Item 2(c). Citizenship:**
Longwood III GP is a limited liability company organized under the laws of the State of Delaware. Longwood III is a limited partnership organized under the laws of the State of Delaware.

**Item 2(d). Title of Class of Securities:**
Common Stock

**Item 2(e). CUSIP Number:**
95075A107

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

See Row 9 of the cover page for each Reporting Person and corresponding footnotes.

**(b) Percent of class:**

See Row 11 of the cover page for each Reporting Person and corresponding footnotes.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See Row 5 of the cover page for each Reporting Person and corresponding footnotes.

**(ii) Shared power to vote or to direct the vote:**

See Row 6 of the cover page for each Reporting Person and corresponding footnotes.

**(iii) Sole power to dispose or to direct the disposition of:**

See Row 7 of the cover page for each Reporting Person and corresponding footnotes.

**(iv) Shared power to dispose or to direct the disposition of:**

See Row 8 of the cover page for each Reporting Person and corresponding footnotes.

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Longwood Fund III GP, LLC**

**Date:** 02/11/2026

**By:** /s/ Robert Hadfield

**Name & Title:** Robert Hadfield, General Counsel

**Longwood Fund III, L.P.**

**Date:** 02/11/2026

**By:** /s/ Robert Hadfield

**Name & Title:** Robert Hadfield, General Counsel of the Reporting Person's general partner